Topic: venture capital (VC)
The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year.
Organ-chip developer Emulate gathered $36 million in VC financing and plans to include a wider range of diseases in its models for drug testing.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
Syncona committed £85 million to Freeline, maintaining a big stake in a biotech that aims to redefine treatment of hemophilia B and Fabry disease.
Mindstrong Health rounded up $15 million in series B financing to continue development of its mental health-tracking smartphone app.
Benchling raised $14.5 million in series B funding to build out its staff and develop its cloud-based data management and collaborative R&D platforms.
The fund is part of an initiative to help British biotechs grow into midsized businesses, rather than sell up at the first sign of a takeover bid.
Alta Partners raised $130 million for its ninth venture capital fund, focusing on biotech and healthcare technology companies.
The multipart agreement includes a $15 million investment, technology development collaboration and a licensing deal.
Juvenescence reeled in $50 million, which will allow it to push forward on its "core projects" and ramp up licensing deals and partnerships.